Advocacy Works for Ophthalmic ASCs
-
By
-
Diane Blanck
-
Michael A. Romansky, JD
-
July 1, 2026
-
3 min
By
Diane Blanck
Michael A. Romansky, JD
July 1, 2026
July 1, 2026
Phase 3 THRIVE and THRIVE-2 trials supported approval following improvements in proptosis and diplopia in active and chronic disease.
June 29, 2026